[HTML][HTML] Low-dose methotrexate for the prevention of atherosclerotic events
Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
[引用][C] Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
PM Ridker, BM Everett, A Pradhan… - … England Journal of …, 2019 - touroscholar.touro.edu
"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events" by Paul M. Ridker, Brendan
M. Everett et al. Home Search Browse Collections My Account About DC Network Digital …
M. Everett et al. Home Search Browse Collections My Account About DC Network Digital …
[PDF][PDF] Low-dose methotrexate for the prevention of atherosclerotic events
PM Ridker, BM Everett, A Pradhan - N Engl J Med, 2019 - researchgate.net
Ischemic heart disease (IHD) with angina and acute myocardial infarction (MI) as its leading
manifestations is the cause of major morbidity and mortality in developed and low-and …
manifestations is the cause of major morbidity and mortality in developed and low-and …
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
PM Ridker, BM Everett, A Pradhan… - New England Journal …, 2019 - cir.nii.ac.jp
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
PM Ridker, BM Everett, A Pradhan… - The New England …, 2018 - europepmc.org
Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
[HTML][HTML] Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
PM Ridker, BM Everett, A Pradhan… - The New England …, 2019 - ncbi.nlm.nih.gov
BACKGROUND Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
PM Ridker, BM Everett, A Pradhan, JG MacFadyen… - 2019 - pubmed.ncbi.nlm.nih.gov
Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
PM Ridker, BM Everett, A Pradhan… - The New England …, 2018 - europepmc.org
Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …